BIOA

BioAge Labs Inc

6.61

Oct 02 • 3:59 PM ET -0.20 (-2.94%)

6.74

Aftermarket • 7:30 PM ET +0.13 (1.97%)

Healthcare Drug Manufacturers - Specialty & Generic USA Small NASD

Peers: SUPN ALKS PRGO BHC INDV HRMY AMRX LNTH TEVA VTRS

| Held by: VTI IWM VXF XPH VTWO IWN IBB FESM SCHA IHE

Scroll to Statements

Index	RUT
Market Cap	303.38M
Enterprise Value	-12.54M
Income	-94.46M
Sales	10.36M
Book/sh	8.19
Cash/sh	6.94
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	62
IPO	Sep 26, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	29.28
P/B	0.81
P/C	0.95
P/FCF	-
EV/EBITDA	-
EV/Sales	-1.21
Quick Ratio	17.19
Current Ratio	17.19
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-2.39
EPS next Y	-2.17
EPS next Q	-0.62
EPS this Y	-8.51%
EPS next Y	10.59%
EPS next 5Y	-4.63%
EPS past 3/5Y	-24.49% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-6.76%
Sales Y/Y TTM	168.06%
EPS Q/Q	3.24%
Sales Q/Q	1.62%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	4.50% 63.65%

Insider Own	32.61%
Insider Trans	-0.42%
Inst Own	60.89%
Inst Trans	9.92%
ROA	-26.27%
ROE	-28.21%
ROIC	-25.05%
Gross Margin	97.58%
Oper. Margin	-1026.28%
Profit Margin	-912.25%
SMA20	-17.06%
SMA50	-37.37%
SMA200	-60.43%
Trades

Shs Outstand	45.78M
Shs Float	30.93M
Short Float	9.94%
Short Ratio	3.60
Short Interest	3.07M
52W High	25.95 -74.53%
52W Low	5.04 31.15%
Volatility	5.53% 5.84%
ATR (14)	0.57
RSI (14)	25.22
Beta	1.09
Rel Volume	1.02
Avg Volume	854.95K
Volume	869,990

Perf Week	-6.24%
Perf Month	-32.07%
Perf Quarter	-73.39%
Perf Half Y	-62.23%
Perf YTD	-50.04%
Perf Year	12.03%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.44
Target Price	35.62
Prev Close	6.81
Price	6.61
Change %	-2.94%

Date	Action	Analyst	Rating Change	Price Target Change
May-27-26	Initiated	Roth Capital	Buy	$36
May-13-26	Initiated	BTIG Research	Buy	$40
Mar-27-26	Initiated	Needham	Buy	$50
Feb-25-26	Initiated	Oppenheimer	Outperform	$60
Feb-18-26	Upgrade	Jefferies	Hold → Buy	$62
Jan-27-26	Initiated	Piper Sandler	Overweight	$73
Dec-05-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$12
Oct-22-25	Upgrade	Citigroup	Neutral → Buy	$10
Feb-28-25	Initiated	William Blair	Mkt Perform
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight	$40 → $5
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$42 → $7
Dec-09-24	Downgrade	Citigroup	Buy → Neutral	$45 → $7
Oct-21-24	Initiated	Morgan Stanley	Overweight	$40
Oct-21-24	Initiated	Jefferies	Buy	$42
Oct-21-24	Initiated	Citigroup	Buy	$45

Show Previous Ratings

Sep-25-26 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Sep-08-26 08:00AM	BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema (GlobeNewswire)
Sep-02-26 08:00AM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-31-26 11:56AM	Number of shares and votes in BioArctic AB (publ) as of August 31, 2026 (PR Newswire)
Aug-05-26 04:50PM	BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
05:56PM	Loading…
Jul-31-26 05:56PM	BIOA, GLUE Stocks Clock Worst Day In Years Whats The NVO Connection? (Stocktwits) -63.62% +19.25%
Jul-14-26 11:39AM	More than 75% of Leqembi-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC 2026 (PR Newswire)
Jun-16-26 08:00AM	BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk (GlobeNewswire)
May-22-26 09:00AM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
May-20-26 09:50AM	Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets (PR Newswire)
May-13-26 09:35AM	AMD, Under Armour downgraded: Wall Street's top analyst calls (The Fly) +5.22%
May-08-26 09:00AM	BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
May-04-26 04:30PM	BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 (GlobeNewswire)
Apr-21-26 07:19AM	BioAge says early data suggest best-in-class potential for inflammation drug (BioPharma Dive)
07:00AM	BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP (GlobeNewswire)
04:30PM	Loading…
Apr-13-26 04:30PM	BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-07-26 08:00PM	Is Amgen (AMGN) Outperforming Other Medical Stocks This Year? (Quartz)
Mar-24-26 09:00AM	BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 (GlobeNewswire) -13.53%
Feb-26-26 10:07PM	BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion (MarketBeat)
Feb-19-26 04:30PM	BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-29-26 03:00AM	Eli Lilly, BioAge chase NLRP3 inhibitors with pipeline in a pill potential (Pharma Voice)
Jan-21-26 10:30PM	BioAge Announces Pricing of Upsized $115.0 Million Public Offering (GlobeNewswire) -5.63% -6.06%
Jan-20-26 04:01PM	BioAge Announces Proposed Public Offering (GlobeNewswire) +5.75%
09:00AM	BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 (GlobeNewswire)
Jan-12-26 01:06PM	BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio (Investor's Business Daily) +27.23%
09:00AM	BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk (GlobeNewswire)
Dec-13-25 10:35AM	2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole (Motley Fool)
Dec-04-25 09:00AM	BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor (GlobeNewswire) +13.88%
Nov-25-25 04:30PM	BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-07-25 09:00AM	BioAge Labs to Present at Jefferies Global Healthcare Conference in London (GlobeNewswire)
04:45PM	Loading…
Nov-06-25 04:45PM	BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-05-25 07:45AM	Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy (Motley Fool)
Oct-29-25 06:15AM	Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? (Motley Fool)
Oct-26-25 06:33PM	BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? (Motley Fool)
Oct-23-25 07:36AM	Ventyx shares soar after study suggests cardiovascular benefits for experimental drug (BioPharma Dive) +31.40%
Aug-20-25 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 07:36AM	BioAge commences dosing in trial of obesity treatment candidate BGE-102 (Clinical Trials Arena)
Aug-15-25 09:00AM	BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor (GlobeNewswire)
Aug-06-25 04:30PM	BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-29-25 10:23AM	BioAge (BIOA) to Analyze Over 17,000 Biobank Samples for Drug Discovery (Insider Monkey)
Jun-21-25 06:00PM	BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions (GlobeNewswire)
Jun-17-25 09:00AM	BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank (GlobeNewswire)
Jun-03-25 09:00AM	BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates (GlobeNewswire)
May-30-25 09:05AM	BioAge Labs completes IND-enabling studies for BGE-102 (TipRanks)
May-29-25 11:18PM	BioAge Labs, Inc. (BIOA)'s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 (Insider Monkey)
09:00AM	BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic (GlobeNewswire)
May-27-25 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
May-06-25 04:30PM	BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-21-25 01:02PM	BioAge Labs, Inc. (BIOA): A Bull Case Theory (Insider Monkey)
Mar-22-25 11:00AM	Investors To Focus On PCE Price Index Print As Cintas, Lululemon To Report Earnings (SeekingAlpha)
Mar-20-25 04:30PM	BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 (GlobeNewswire)
Mar-17-25 01:54PM	BioArctic receives Orphan Drug Designation for exidavnemab the US (PR Newswire)
Mar-04-25 05:07AM	BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman (Newsfile)
Feb-20-25 04:30PM	BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference (GlobeNewswire)
10:36AM	BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman (Newsfile)
Feb-16-25 07:18AM	BIOA COURT NEWS: BioAge Labs has been Sued for Securities Violations; Contact BFA Law by March 10 if You Lost Money (NASDAQ:BIOA) (GlobeNewswire)
Feb-14-25 05:45AM	Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire) +5.97%
Feb-13-25 08:42AM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (Newsfile)
Feb-07-25 05:45AM	BioAge Labs, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-30-25 09:01AM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (Newsfile)
Jan-29-25 05:39AM	BioAge drops obesity drug; Akero, 89bio cash in on MASH data (BioPharma Dive) -6.40%
Jan-28-25 07:27PM	Kessler Topaz Meltzer & Check, LLP Encourages BioAge Labs, Inc. Investors with Losses to Contact the Firm (PR Newswire)
09:00AM	BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs (GlobeNewswire)
Jan-24-25 05:45AM	Shareholders of BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-22-25 03:00AM	After an obesity stumble, BioAge reconnects with its longevity pipeline (Pharma Voice)
Jan-21-25 05:45AM	Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-18-25 03:07AM	BIOAGE LABS (BIOA) Investors are Notified the Company has been Sued and are Urged to Contact BFA Law by March 10 (Newsfile)
Jan-06-25 09:00PM	Bragar Eagel and Squire, P.C. Is Investigating Franklin, MediaAlpha, e.l.f. Beauty, and BioAge and Encourages Investors to Contact the Firm (GlobeNewswire) -7.39%
Jan-03-25 12:51PM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (PR Newswire)
Jan-02-25 09:35AM	BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-01-25 05:00AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile)
Dec-27-24 11:32AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -6.46%
09:18AM	BioAge Labs, Inc. (BIOA): A Bull Case Theory (Insider Monkey)
Dec-26-24 07:23AM	Kirby McInerney LLP is Investigating Potential Shareholder Claims Against BioAge Labs, Inc. (BIOA) (Newsfile)
Dec-25-24 07:04AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile)
Dec-23-24 10:19AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
Dec-19-24 01:15PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) +20.23%
05:46AM	BioAge and Novartis seek drug targets for ageing-related diseases (Pharmaceutical Technology)
Dec-18-24 09:00AM	BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions (GlobeNewswire)
Dec-16-24 04:20PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
03:00AM	3 closely watched drugs that failed in the clinic (Pharma Voice)
Dec-13-24 10:31AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile) -6.75%
Dec-12-24 06:34PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
Dec-09-24 07:51PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -76.85%
09:28AM	BioAge halts ongoing Phase II trial of obesity drug due to liver concerns (Clinical Trials Arena)
07:41AM	Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns (Benzinga)
Dec-07-24 06:34AM	BioAge shares tumble after decision to halt obesity drug study (BioPharma Dive)
Dec-06-24 04:35PM	BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity (GlobeNewswire) +9.36% -76.85%
Dec-05-24 04:30PM	BioAge Labs to Present at Goldman Sachs Year-Ahead Catalyst Clinic (GlobeNewswire)
Dec-04-24 04:47PM	Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now? (Insider Monkey)
Nov-21-24 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 11:01PM	BioAge Labs Reports Strong Q3 2024 Achievements (TipRanks) -11.78%
Nov-07-24 04:30PM	BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -10.11% +7.61%
Nov-04-24 09:00AM	BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 (GlobeNewswire)
Oct-24-24 09:00AM	BioAge Labs to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 10:53AM	Wall Street analysts initiate coverage of BioAge Labs (Investing.com) +8.26%
Oct-17-24 09:45AM	Prediction: These 2 Stocks Could Soar in 2025 (Motley Fool)
Oct-12-24 02:31PM	Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock (Motley Fool)
Oct-07-24 09:10PM	RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc (GuruFocus.com)
Oct-05-24 07:15AM	3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October (Motley Fool)

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.

PhDKristen Fortney

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Barton Shane	Principal Accounting Officer	Jun 29 '26	Option Exercise	6.61	39,718	262,542	42,350	Jul 01 04:27 PM
Barton Shane	Principal Accounting Officer	Jun 30 '26	Option Exercise	6.53	20,216	132,017	20,216	Jul 01 04:27 PM
Barton Shane	Principal Accounting Officer	Jun 29 '26	Sale	25.21	42,350	1,067,576	0	Jul 01 04:27 PM
Barton Shane	Principal Accounting Officer	Jun 30 '26	Sale	25.19	20,216	509,176	0	Jul 01 04:27 PM
Barton Shane	Officer	Jun 30 '26	Proposed Sale	25.19	20,216	509,177		Jun 30 04:21 PM
Barton Shane	Officer	Jun 29 '26	Proposed Sale	25.21	42,350	1,067,578		Jun 29 04:35 PM
GOLDSTEIN DOV A MD	Chief Financial Officer	Apr 23 '26	Option Exercise	4.38	3,542	15,514	36,575	Apr 24 04:19 PM
RUBIN PAUL D	Chief Medical Officer	Apr 01 '26	Option Exercise	5.05	8,820	44,572	8,820	Apr 03 04:07 PM
RUBIN PAUL D	Chief Medical Officer	Apr 01 '26	Sale	17.81	8,820	157,084	0	Apr 03 04:07 PM
RUBIN PAUL D	Officer	Apr 01 '26	Proposed Sale	17.81	8,820	157,084		Apr 01 10:53 AM
RUBIN PAUL D	Chief Medical Officer	Mar 02 '26	Option Exercise	4.77	7,433	35,470	7,433	Mar 03 04:46 PM
RUBIN PAUL D	Chief Medical Officer	Mar 02 '26	Sale	20.30	7,433	150,890	0	Mar 03 04:46 PM
GOLDSTEIN DOV A MD	Chief Financial Officer	Mar 01 '26	Option Exercise	4.38	3,542	15,514	33,033	Mar 03 04:44 PM
RUBIN PAUL D	Officer	Mar 02 '26	Proposed Sale	20.03	7,433	148,883		Mar 02 10:17 AM
RUBIN PAUL D	Chief Medical Officer	Feb 02 '26	Option Exercise	4.77	7,433	35,470	7,433	Feb 03 04:26 PM
RUBIN PAUL D	Chief Medical Officer	Feb 02 '26	Sale	18.75	7,433	139,369	0	Feb 03 04:26 PM
GOLDSTEIN DOV A MD	Chief Financial Officer	Feb 01 '26	Option Exercise	4.38	3,541	15,510	29,491	Feb 03 04:23 PM
RUBIN PAUL D	Officer	Feb 02 '26	Proposed Sale	18.75	7,433	139,369		Feb 02 09:43 AM
GOLDSTEIN DOV A MD	Chief Financial Officer	Jan 16 '26	Option Exercise	4.38	3,542	15,514	25,950	Jan 21 04:20 PM
GOLDSTEIN DOV A MD	Chief Financial Officer	Jan 13 '26	Option Exercise	8.39	27,000	226,530	49,408	Jan 15 04:22 PM
GOLDSTEIN DOV A MD	Chief Financial Officer	Jan 13 '26	Sale	19.70	27,000	531,828	22,408	Jan 15 04:22 PM
Fortney Kristen	Chief Executive Officer	Jan 13 '26	Sale	18.12	233,107	4,223,036	976,949	Jan 15 04:20 PM
Fortney Kristen	10% Owner	Jan 13 '26	Proposed Sale	18.00	233,107	4,195,926		Jan 13 04:36 PM
GOLDSTEIN DOV A MD	Officer	Jan 13 '26	Proposed Sale	19.70	27,000	531,828		Jan 13 04:16 PM
RUBIN PAUL D	Chief Medical Officer	Jan 02 '26	Option Exercise	4.77	7,433	35,470	7,433	Jan 06 04:24 PM
RUBIN PAUL D	Chief Medical Officer	Jan 02 '26	Sale	12.85	7,433	95,490	0	Jan 06 04:24 PM
RUBIN PAUL D	Officer	Jan 02 '26	Proposed Sale	13.41	7,433	99,677		Jan 02 12:56 PM
RUBIN PAUL D	Chief Medical Officer	Dec 09 '25	Option Exercise	6.57	18,000	118,260	18,000	Dec 11 04:21 PM
RUBIN PAUL D	Chief Medical Officer	Dec 09 '25	Sale	12.00	18,000	216,000	0	Dec 11 04:21 PM
RUBIN PAUL D	Officer	Dec 09 '25	Proposed Sale	12.00	18,000	216,000		Dec 09 11:23 AM
RUBIN PAUL D	Chief Medical Officer	Dec 04 '25	Option Exercise	4.11	68,897	283,167	68,897	Dec 05 06:20 PM
RUBIN PAUL D	Chief Medical Officer	Dec 04 '25	Sale	10.19	68,897	701,909	0	Dec 05 06:20 PM
RUBIN PAUL D	Officer	Dec 04 '25	Proposed Sale	10.19	68,897	701,912		Dec 04 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BIOA

BioAge Labs Inc

Upgrade your Finviz experience